These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24460701)

  • 1. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
    Myint TM; Rangan GK; Webster AC
    Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
    Griffiths J; Mills MT; Ong AC
    BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
    Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Jo WR; Kim SH; Kim KW; Suh CH; Kim JK; Kim H; Lee JG; Oh WY; Choi SE; Pyo J
    Eur J Radiol; 2017 Oct; 95():56-65. PubMed ID: 28987699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
    Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
    PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K; Trott JF; Gao G; Chapman A; Weiss RH
    BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
    Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA
    Drugs; 2019 Feb; 79(3):303-313. PubMed ID: 30689194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    Liu YM; Shao YQ; He Q
    Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
    Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.